COMMUNIQUÉS West-GlobeNewswire

ESPERITE (ESP) expects publication of Annual Report 2017 before 17 November 2018

09/11/2018 - 07:18

Amsterdam, The Netherlands - 09 November 2018 Esperite announces that the preparation of its Annual Report 2017 is nearly finalized and expects the publication of its Annual Report 2017 before 17 November 2018. About [...]

Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

09/11/2018 - 06:00

Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor -directed T-cell and Natural Killer (NK) Cell Responses Targets 5T4 Cancer Antigen Present on Many Types of Solid Tumors LUND, Sweden and SEATTLE, Nov [...]

Intuitive Announces New General Manager in Korea

09/11/2018 - 02:18

SUNNYVALE, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq: ISRG), has named Austin Kim as Vice President and General Manager in Korea, where he will direct business strategy and operations [...]

OV - Update Regarding Participation at Investor Events in Q4 2018

09/11/2018 - 01:59

Investor news Hørsholm, Denmark and Cambridge, MA, US, November 5 th , 2018 - Oncology Venture A/S ("Oncology Venture") today provided an update regarding when members of its senior management team are scheduled to make [...]

Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock

09/11/2018 - 01:13

CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering [...]

Viveve to Present at Stifel 2018 Healthcare Conference

08/11/2018 - 23:30

ENGLEWOOD, Colo., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and [...]

Cidara Provides Corporate Update and Reports Third Quarter 2018 Financial Results

08/11/2018 - 23:23

SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three [...]

ADMA Biologics Reports Third Quarter 2018 Financial Results

08/11/2018 - 23:05

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, [...]

Innovation Pharmaceuticals Provides Corporate Update Highlighting Business Development and Clinical Pipeline Priorities

08/11/2018 - 23:00

BEVERLY, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a corporate update highlighting business [...]

Radient Technologies Inc. Announces AGM Results and Completion of Shares for Debt Transaction

08/11/2018 - 23:00

EDMONTON, Alberta, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI ) today announces that all resolutions were passed by the requisite majority at its annual [...]

Extendicare Announces 2018 Third Quarter Results

08/11/2018 - 23:00

MARKHAM, Ontario, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and nine months ended September 30, 2018. Results are presented in [...]

Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference

08/11/2018 - 23:00

CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs [...]

Merus sera présente à la Jefferies 2018 London Healthcare Conference

08/11/2018 - 22:49

UTRECHT, Pays-Bas, 08 nov. 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), entreprise d'immuno-oncologie de stade clinique qui développe des traitements innovants à base d'anticorps bispécifiques (Biclonics®), a [...]

Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China

08/11/2018 - 22:48

- 50/50 joint venture with investor syndicate led by Vivo Capital – - Expands global reach for TransCon products – COPENHAGEN, Denmark, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a [...]

Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment

08/11/2018 - 22:44

New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is pleased to announce [...]

Intellia Therapeutics to Present at November Healthcare Investor Conferences

08/11/2018 - 22:30

CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and [...]

Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial Results

08/11/2018 - 22:30

Company Executing on Lead Programs CPI-1205 and CPI-0610 Expects to Evaluate Proof of Concept for Both Programs in Mid-2019 CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc., ( [...]

Denali Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights and Announces the Appointment of Jennifer Cook to Board of Directors

08/11/2018 - 22:30

SOUTH SAN FRANCISCO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today [...]

Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results

08/11/2018 - 22:30

Third quarter 2018 total revenues of $28.0 million including net U.S. Auryxia ® (ferric citrate) product sales of $26.6 million, a 96 percent increase compared to the third quarter of 2017 Approximately 47,500 Auryxia [...]